Key takeaways
- Mysimba contains naltrexone and bupropion and acts on pathways involved in appetite; Xenical contains orlistat and reduces dietary fat absorption. Mysimba and Xenical assessments.
- Both have evidence for weight management alongside dietary and activity support, but neither guarantees a particular loss. EMA evidence summaries.
- Opioid use is a major safety issue with Mysimba. EMA opioid advice.
- Orlistat’s bowel effects do not mean it has no other risks or interactions. Xenical product information.
Choosing between these medicines starts with your medical history, not a ranking of which causes the most weight loss. For one person, an opioid pain medicine may rule out Mysimba. For another, bowel symptoms may make orlistat difficult to sustain.
These are different treatments, not brand and generic versions of the same product.
How do Mysimba and Xenical differ?
Mysimba influences appetite-related pathways; Xenical reduces the absorption of some fat from food.
| Question | Mysimba | Xenical |
|---|---|---|
| Active ingredient | Naltrexone plus bupropion | Orlistat |
| Main treatment effect | Acts on appetite and food-intake pathways | Acts on fat-digesting enzymes in the gut |
| Common tolerability issue | Nausea, vomiting or constipation | Oily stools, leakage or urgency |
| Key discussion before treatment | Opioids, blood pressure and seizure history | Bowel or liver conditions and medicine interactions |
The EMA assessments describe benefits alongside reduced-calorie diets and support. They do not justify labels such as “for emotional eaters” or “for people who lack discipline”. Those descriptions oversimplify both eating behaviour and treatment.
Which produces more weight loss?
Separate trial averages cannot reliably predict which medicine will work better for you.
In three Mysimba studies, average weight loss was 3.7% to 5.7%, compared with 1.3% to 1.9% with placebo. A fourth study used more intensive counselling and recorded 8.1% versus 4.9%. Around half the participants did not complete a year, so the method used to account for them affected the results. These are total losses, including the effect of the wider weight-loss programme. Mysimba trials.
The Xenical summary reports weight in kilograms: across seven studies, the average loss after a year was 6.1 kg with Xenical and 2.6 kg with placebo. These were different studies and participants, with dietary support in both groups. Comparing those kilogram figures directly with Mysimba percentages would not rank the medicines fairly. Xenical trials.
Ask the prescriber what counts as a worthwhile response and when treatment will be reassessed. The EMA summaries specify response checkpoints for both medicines. The point of a checkpoint is to avoid continuing something that is not providing enough benefit. Mysimba assessment, Xenical assessment.
Why are opioids important with Mysimba?
Naltrexone can interfere with opioid treatment, so pain medicines and planned surgery must be discussed before prescribing.
This includes medicines you may know by a brand rather than by the word opioid. Bring the names of painkillers, cough remedies and treatments for opioid dependence. Do not try to overcome opioid blockade by taking more pain medicine. EMA opioid advice.
INFORMUS is a randomised study comparing Mysimba with placebo to investigate cardiovascular outcomes beyond 12 months. The EMA lists its expected results date as 2028 and requires annual progress reports from the manufacturer. Cardiovascular safety beyond the first year remains uncertain. Each year, the prescriber must review cardiovascular risk and continued benefit; the European rule is to stop after year one if a loss of at least 5% of starting weight has not been maintained. Mysimba referral and safety measures.
Mysimba is also unsuitable with a history of seizures or uncontrolled high blood pressure. Certain psychiatric conditions can rule it out too. The prescriber needs that history as well as the medicines list.
What makes the decision practical in South Africa?
Agree on the review dates, their cost and the response needed to continue treatment.
The European response checkpoints are different: Mysimba should be stopped if less than 5% of starting weight has been lost after 16 weeks; Xenical has a 5% checkpoint at 12 weeks. Ask the prescriber how the response, side effects and ongoing costs will be reviewed, and what to do if the next pack cannot be obtained. Mysimba review and Xenical assessment.
For the pack prescribed to you, check South African supply requirements and current availability. The European approvals cited here do not establish South African registration.
Our Rybelsus guide covers oral semaglutide for diabetes and the risks of substituting it for an injectable weight-management medicine.
Do and don’t
Do:
- Include occasional codeine or morphine in the medicine list. Mention methadone or buprenorphine treatment as well.
- Agree on the 16-week Mysimba or 12-week Xenical checkpoint and how to report troublesome side effects.
Don’t:
- Combine weight-loss medicines without a prescriber’s plan.
- Treat average trial weight loss as a promise or a judgement about effort.
